Efficacy of Intraosseous Tranexamic Acid in Primary Total Hip Arthroplasty: A Prospective Randomized Controlled Trial.
J ArthroplastyJun 22, 2026 (epub)
Clinical ResearchOrthopedic Surgery
Yongjie Chen, Li Cao, Baochao Ji et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the efficacy of intraosseous (IO) tranexamic acid (TXA) in 126 patients undergoing primary total hip arthroplasty. The study found that IO TXA administration was noninferior to intravenous (IV) and topical routes regarding hemoglobin reduction. Notably, the IO group exhibited lower mean calculated total blood loss on the day of surgery and postoperative day one.
Key findings
- Mean hemoglobin reduction was comparable across all groups on the day of surgery and postoperative days one to three (P > 0.431).
- IO group showed lower mean calculated total blood loss on the day of surgery and postoperative day one (P = 0.005 and 0.016, respectively).
- Transfusion rates were 2.3% for IO, 7.1% for IV, and 2.3% for topical groups (P = 0.434).
Why it matters
Understanding the optimal route for TXA administration can help clinicians minimize blood loss and transfusion needs in total hip arthroplasty, potentially improving patient outcomes and resource utilization.